The Scottish pharma company is expected to launch its testosterone replacement therapy Tostran in the UK in the next two weeks. Aimed at men aged 40 and over, Tostran is a prescription gel applied to the genital area.
Following a four-way battle, Aquamarine will look after external comms, while Bedgebury Consulting will handle internal comms.
The external PR campaign will raise awareness of the short and long-term health implications of testosterone deficiency,
Aquamarine founder Charlotte Messer will lead the programme, which will initially target GPs, and subsequent consumer work.